Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Transcytosis of IgG

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...

Clinical Applications of Epidermal Stem Cells

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...

Immunodeficiency Diseases

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An essential role for the Zn<sup>2+</sup> transporter ZIP7 in B cell development.

Nature immunology·2019

Same author

Supplement: Frontiers in Immunoglobulin Therapy of Primary Immunodeficiency Disease.

Journal of clinical immunology·2017

Same author

Case Studies.

Journal of clinical immunology·2017

Same author

Facilitating home-based treatment of hereditary angioedema.

Allergy and asthma proceedings·2015

Same author

Training hereditary angioedema patients to self-administer intravenous C1 esterase inhibitor concentrate.

Journal of infusion nursing : the official publication of the Infusion Nurses Society·2014

Same author

Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes.

Journal of clinical immunology·2014

Search research articles

Related Experiment Video

Updated: May 15, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

Why I use subcutaneous immunoglobulin (SCIG).

Ralph S Shapiro¹

¹Midwest Immunology Clinic, 157300 37th Avenue, Suite 100, Plymouth, MN 55446, USA. rsshapi@hotmail.com

Journal of Clinical Immunology

|December 25, 2012

Summary

Subcutaneous immunoglobulin (SCIG) replacement therapy offers significant advantages over intravenous immunoglobulin (IVIG) for primary immunodeficiency disease (PIDD) patients, enhancing independence and quality of life.

Area of Science:

Immunology
Pharmacology
Patient Care

Background:

Immunoglobulin (IgG) replacement is crucial for treating primary immunodeficiency disease (PIDD).
Multiple IgG replacement routes exist, necessitating individualized treatment choices.
The subcutaneous (SCIG) route is increasingly preferred over the intravenous (IVIG) route.

Purpose of the Study:

To highlight the advantages of subcutaneous immunoglobulin (SCIG) replacement therapy.
To compare SCIG with intravenous immunoglobulin (IVIG) for PIDD patients.
To advocate for SCIG as a preferred treatment option.

Main Methods:

This is a review and preference-based discussion of existing treatment modalities.
Comparison of SCIG and IVIG based on clinical experience and literature.

More Related Videos

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

Related Experiment Videos

Last Updated: May 15, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

Evaluation of patient outcomes and administration factors.

Main Results:

SCIG offers independence from hospital settings and flexibility in dosing.
SCIG is suitable for patients with poor venous access and better tolerated than IVIG.
SCIG demonstrates a favorable side-effect profile, more stable IgG levels, and improved quality of life.
SCIG administration is less costly than IVIG.

Conclusions:

Subcutaneous immunoglobulin (SCIG) offers numerous advantages over intravenous immunoglobulin (IVIG) for PIDD management.
SCIG provides enhanced patient independence, tolerability, and quality of life.
SCIG is a highly recommended IgG replacement therapy for most PIDD patients.